MI-K: Pharmacokinetics of Micafungin in Patients of Intensive Care Units
Study Details
Study Description
Brief Summary
Invasive fungal infections (IFIs) are a frequent cause of morbidity and mortality in high-risk patients, such as immunocompromised patients. Candida is currently the predominant fungal pathogen in these patient populations and is associated with significant morbidity and a high mortality.
Micafungin (MCF) is a semisynthetic compound belonging to the new class of antifungal agents, the echinocandin lipopeptides, that has potent in vitro and experimental in vivo activity against a variety of pathogenic Candida species and Aspergillus species. Its applied indications are so the treatment and/or the prophylaxis of Candida and Aspergillus infections. MCF is currently licensed for the treatment of candidiasis at doses of either 100 or 150 mg a day.
The efficacy of MCF is linked to the area under the concentration-time curve over 24 h in the steady state divided by the MIC (AUC0-24/ MIC ratio).
On one hand:
- It was demonstrated that 98% of invasive candidiasis patients with a MCF AUC/MIC ratio between 3 and 12 achieve microbiological clearance, as opposed to only 85% of those with an AUC/MIC ratio < 3. In the case of infections by Candida parapsilosis, which exhibits drug MICs that are 50- to100-fold higher, 100% of patients with an AUC/MIC ratio >285 achieve microbiological clearance, as opposed to 82% of those below that exposure level.(1)
On the other hand:
-
It is well known that patients of intensive care units (ICU) are characterized by particular pharmacokinetic parameters with higher apparent volume of distribution (VC/F) and/or higher apparent systemic clearance (CL/F). In a population of healthy volunteers, it was observed that CL/F of MCF presents a high interpatient variability.(2)
-
Whether most ICUs patients achieve optimal AUC/MIC ratio thresholds at standard doses has not been investigated so far. In particular, lower AUCs might be reached in patients having the highest VC/F values. Such patients would then be at risk of therapy failure and would benefit from individualized-dosing strategies.
In this context, the study of the pharmacokinetics of MCF in critically ill patients seems to be necessary.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 4 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Other: Pharmacokinetics of micafungin
|
Other: micafungin
This is a pharmacokinetic study where a total number of 14 blood samples will be drawn per patient. Clinical and biological data will be concomitantly collected.
|
Outcome Measures
Primary Outcome Measures
- To describe micafungin concentrations over time, [3 weeks]
The evaluation of the PK model performance will be based on its ability: To describe micafungin concentrations over time, To explain the sources of inter-individual PK variability. It will be done by the calculation of the bias between concentrations predicted using the model and observed concentrations.
Secondary Outcome Measures
- To estimate the proportion of patients hospitalized in an ICU achieving the target AUC or AUC/MIC when receiving the recommended regimen [3 weeks]
The estimation of the proportion of patients hospitalized in an ICU achieving the target AUC or AUC/MIC when receiving the recommended regimen will be based on the determination of exposure indices (AUC) and mycological characteristics (fungus and its MIC)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Critically ill patients hospitalized in an ICU, with suspected or proven invasive fungal infections, for whom the decision has been made to start a treatment based on MCF.
-
Age > 18 years.
-
Patients willing to give their written informed consent for their participation to the study.
-
Patients affiliated to the French social security system or equivalent.
Exclusion Criteria:
-
Patient for whom a treatment based on MCF has already been started
-
Patient who have benefited from bone marrow transplantation
-
Age < 18 years
-
Patient under legal protection
-
Patient deprived of liberty
-
Pregnant or breast-feeding woman or woman of childbearing potential without efficient contraception (based on declaration)
-
Patient with any altered mental status or any psychiatric condition that would interfere with the understanding of the study
-
Patient enrolled in another clinical trial testing drugs or therapeutic strategies (including the so-called "exclusion period")
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | CHU de Montpellier | Montpellier | France | 34295 |
Sponsors and Collaborators
- University Hospital, Limoges
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- I13025